majority of the clinical cases present themselves as metastasized or unresectable forms of PanC, the frontline chemotherapeutic agent currently used in clinic is gemcitabine, a nucleoside analog.
Gemcitabine is extensively applied in PanC therapy alone or in combination with other approved cytotoxic agents (5-fluorouracil, cisplatin, oxaliplatin, etc.) and biological agents (erlotinib, bevacizumab, etc.). 5 However, there has been a constant increase in resistance to gemcitabine therapy in PanC patients and the survival outcome is recurrently poor. 6 PanC usually arises as noninvasive precursor lesion namely pancreatic intraepithelial neoplasia (PanIN) and gradually evolves to the advanced metastatic form of pancreatic ductal adenocarcinoma (PDAC). PDACs are the most commonly occurring form of PanC (90%), with mutated KRAS expressed in ≥95% of cases. Other frequently mutated genes present in ≥50% of PanC types are p16/CDKN2A, TP53, and SMAD4.
7
Other than genetic alterations, in recent years, cancer stem cells (CSCs) have been identified to play a major role in cancer progression and recurrence in pancreatic as well as other cancers. 8, 9 PanC-CSCs were first identified in 2007 by Li et al., 8 in established human PanC xenografts of NOD/SCID mice. CSCs are the cells comprising a very small part (∼1%) of the entire tumor mass, with the ability to self-renew and give rise to phenotypically and functionally heterogeneous cancer cell lineages found within the tumor itself. 10 While they share the core regulatory pathways with normal stem cells, CSCs are known to undergo reprograming and transformation, resulting in their multi-lineage differentiation and self-renewal potential. 11 Owing to their stem cell like properties, although a small population, CSCs are known to mediate initiation, progression, metastasis, relapse and drug resistance in variety of cancers including PanC. 12 It has been frequently reported that CSCs are responsible in inducing chemoresistance and lead to accelerated progression of PanC to its more aggressive and invasive forms. 13 The idea therefore remains to target the PanC-CSC pool using novel agents with elevated anticancer and therapeutic potential, and negligible toxicity to the surrounding normal tissue.
Taken together, it is clear that several efforts are being made to control, manage, and treat PanC; however, conventional chemotherapeutic drugs have drug-resistance and often fail to effectively target and eliminate CSCs, thereby resulting in tumor relapse and metastasis. This feature is further emphasized in PanC particularly; mainly credited to its high intrinsic resistance resulting from relatively higher percentage and enrichment of CSCs following chemotherapeutic regimes. 14 Cell signaling (Beverly, CA), and OCT4 and CD44 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
| BMJ preparation
Chinese variety of commercially available bitter melon was used for our study. The fruits were washed with water and air dried. Once the water was completely drained, the melons were cut open, deseeded and the remaining fruit was juiced using a household juicer. The juice was then subjected to centrifugation at 3000g for 30 min. The supernatant was collected, sterile filtered, and aliquoted for storage at −80°C, while the pellet was discarded. Media was replenished, and EGF (20 ng/mL) and FGF (10 ng/mL)
were added at every 72 h. In a parallel study, cells were allowed to generate spheroids for 4-5 days, which were then treated with exogenous addition of BMJ (2% and 4%, v/v; data not shown for 4%)
for 11 days to study the effect of BMJ on mature spheroids. 
| Statistical analysis
All statistical analyses were performed using Sigma Stat software (version 3.5, Jandel Scientific). Quantitative data are presented as mean ± SEM. Statistical significance of difference between control and treatment groups was determined through one-way analysis of variance (ANOVA) followed by Tukey's test for multiple comparisons.
P<0.05 was considered significant. P value of P ≤ 0.05 is denoted by *, P ≤ 0.01 is denoted by ** and P ≤ 0.001 is denoted by ***. BMJ, a dietary agent extracted from the fruits of Momordica charantia, has numerous associated health benefits; antidiabetic, emetic and laxative. 35 Studies using BMJ/BMJ-extracts in animals show lower serum cholesterol levels, hypoglycemia and delayed onset of tumorigenesis, alongside improved glucose tolerance in human subjects without significant alterations to insulin levels with BMJ administration. [36] [37] [38] Component analysis of bitter melon characterizes all the important constituents with multiple beneficial effects, mainly cucurbitane-type triterpenoids, triterpene glycoside, phenolic acid, flavonoids, essential oils, fatty acids, saponins and amino acids. 35 The toxicity data is minimal with only evident side effects being diarrhea and abdominal pain that can be relatively easily managed. 39 Variety of bitter melon constituents have actively been screened for their anticancer potential in numerous cancer types. 35 Analysis of bitter melon methanolic extract showed cucurbitane-type triterpenoids to be associated with an elevated anticancer efficacy in a two-stage mouse skin carcinogenesis model. 40 Furthermore, purified fractions of bitter melon methanolic extract containing monogalactosyl diacylglycerol (MGDG, a The current study exclusively revolves around BMJ and its anticancer efficacy against PanC exerted through CSC modulation. 
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